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Coronavirus disease 2019 (COVID-19) due to a novel virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global 
pandemic that has resulted in over 1.5 million confirmed cases and close to 100 000 deaths. In the majority of symptomatic cases, COVID-19 
results in a mild disease predominantly characterised by upper respiratory tract symptoms. Reverse transcription polymerase chain reaction 
(RT-PCR) using a nasopharyngeal sample is the mainstay of diagnosis, but there is an ~30% false negative rate early in the disease and in 
patients with mild disease, and therefore repeat testing may be required. RT-PCR positivity can persist for several days after resolution of 
symptoms. IgM and IgG antibody responses become positive several days after the onset of symptoms, and robust antibody responses are 
detectable in the second week of illness. Antibody-based immunoassays have a limited role in the diagnosis of early symptomatic disease. 
However, their incremental benefit over RT-PCR in the first 2 weeks of illness is currently being clarified in ongoing studies. Such assays 
may be useful for surveillance purposes. However, their role in potentially selecting individuals who may benefit from vaccination, or as 
a biomarker identifying persons who could be redeployed into essential employment roles, is being investigated. Rapid antibody-based 
immunoassays that detect viral antigen in nasopharyngeal samples are being developed and evaluated.
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Coronavirus disease 2019 (COVID-19) due to a novel virus, severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a 
global pandemic. There are more than 1.5 million confirmed cases 
across almost every country in the world, and at the time of writing 
(early April 2020) there were close to 100 000 recorded deaths.[1] The 
diagnosis of COVID-19 can be challenging, and as with any disease 
entity, a number of factors, including disease stage, disease prevalence, 
patient profile and sample type and quality, can influence diagnostic 
test performance. In this review we outline the performance outcomes 
of key tests used to diagnose COVID-19, and considerations that 
modulate performance. The safety of healthcare workers collecting 
samples, laboratory safety aspects and experimental approaches such 
as detection of volatile organic compounds in exhaled breath, mass 
spectrometry studies of different sample types, methods of signal 
amplification and utility of other novel approaches are not discussed 
here.
Indications for testing
Country-specific indications and criteria for testing have evolved 
rapidly, and are being updated as information emerges and as the 
epidemic progresses. These recommendations have been guided by 
the phase of the epidemic and available resources. Generally speaking, 
testing for COVID-19 should currently be considered in anyone with 
symptoms of an acute respiratory tract infection (upper or lower) 
and with or without systemic symptoms such as fever, fatigue and 
myalgia.[2-5] In mild disease, testing directs the need for self-isolation 
and identification of new cases through contact tracing and testing 
of contacts. As the epidemic progresses, and with forecasted limited 
testing capacity, testing may be directed to specific subgroups or those 
with enhanced risk of a poor outcome.
The differential diagnosis
In the clinical setting, COVID-19 will form part of the differential 
diagnosis of any acute respiratory presentation, including infectious 
causes of pneumonia (e.g. bacterial, influenza, other viral pneumonia, 
pneumocystis pneumonia, tuberculosis (TB), etc.), acute exacerbations 
of asthma and chronic obstructive pulmonary disease (COPD), acute 
pulmonary embolism, cardiac failure and other conditions. Relevant 
investigations will depend on the clinical context, and will likely include 
pulmonary imaging, relevant laboratory investigations, blood cultures 
and interrogation of urine and/or lower respiratory tract specimens to 
rule in a viral, mycobacterial, fungal and/or bacterial cause. Clinical 
Diagnosis of COVID-19: Considerations, controversies and 
challenges
K Dheda,1,2 MB BCh, FCP (SA), FRCP (UK), PhD; S Jaumdally,1 MPH, PhD; M Davids,1 BSc (Hons), PhD; J-W Chang,1 BSc (Hons), MSc, PhD;  
P Gina,1 MB BCh, FCP (SA); A Pooran,1 BSc (Hons), MSc, PhD; E Makambwa,1 MB BCh, FCP (SA); A Esmail,1 MD, FCP (SA);   
E Vardas,3 BSc (Hons), MB BCh, DTM&H, DPH, MMed (Virology), FC Path Clinical Virology;       
W Preiser,4,5 Dr Med, Dr Med Habil,WP, DTM&H, MRCPath
1  Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute and South African MRC/UCT Centre for 
the Study of Antimicrobial Resistance, University of Cape Town, South Africa
2 Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, UK
3 Lancet Laboratories, Johannesburg, South Africa 
4 Division of Medical Virology, Department Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
5 National Health Laboratory Service, Cape Town, South Africa
Corresponding author: K Dheda (keertan.dheda@uct.ac.za)
30   AJTCCM  VOL. 26  NO. 2  2020
AJTCCM  VOL. 26  NO. 2  2020   31
RESEARCH
and laboratory parameters that may suggest viral infection include 
pyrexia, acute malaise and myalgia, and lymphopenia. C-reactive 
protein is unhelpful in distinguishing COVID-19 from other 
infections. Procalcitonin is elevated in severe COVID-19 and when there 
is secondary bacterial infection.[6,7] In early disease low procalcitonin 
may distinguish COVID-19 from bacterial infections, but not from 
other viral diseases (data are awaited to confirm this supposition). In 
those with underlying asthma or COPD the presence of pulmonary 
infiltrates may favour a respiratory infection-related cause, though a 
cardiac cause must also be considered in the differential diagnosis. 
The biological sample of interest
The most common sample types sent for testing, usually by means 
of reverse transcription polymerase chain reaction (RT-PCR), are 
nasopharyngeal and oropharyngeal samples obtained using a swab, 
placed in viral transport medium. There is already considerable 
shortage of reagents (and swabs), meaning that dry swabs are being 
sent to laboratories in some centres. Dry swabs are less costly and 
more conducive to community-based testing, but data are urgently 
required to determine the comparative sensitivity of dry swabs 
compared with using viral transport medium (taking into account the 
time from sample acquisition to sample processing). Samples from the 
lower respiratory tract including sputum, tracheal aspirate, bronchial 
washings and bronchoalveolar lavage may also be sent. In patients 
with COVID-19 disease, samples from the lower respiratory tract are 
more likely to test positive (discussed below). Viral RNA can also be 
detected in stool in ~30% of cases, and in blood in ~1% of cases,[8] but 
rarely in urine. 
Clinic al  and immuno diagnostic 
trajectory of COVID-19 and sampling 
considerations 
Recent data from infections in special contexts such as cruise liners[9] 
and in close contacts of COVID-19 patients[10] have demonstrated 
that SARS-CoV-2-specific RT-PCR may be positive in the early 
phase of the disease, and that viral shedding in the asymptomatic 
phase and in the early prodromal phase can be considerable.[11,12] At 
present, screening of asymptomatic individuals by RT-PCR has been 
constrained by limited testing capacity, and the need to focus public 
health efforts and resources on symptomatic persons.
In symptomatic individuals, 80 - 90% of patients have mild symptoms 
not requiring hospitalisation. Depending on age and the presence of 
risk factors, ~10 - 20% of symptomatic persons may require admission 
to hospital because of respiratory or other complications. Individuals 
in this enhanced risk category may have one or more such factors, 
including age >50 years, comorbidities, history of significant tobacco 
smoking and underlying immunocompromising illnesses.[10,13] In mild 
disease, especially in the early stages, the RT-PCR false negative rate is 
~30 - 40%.[8,14,15] A meta-analysis reported that a single test ~10 days 
post symptom development had an ~33% false negative rate using 
a nasopharyngeal swab (52.89% for a throat swab).[16] Ai et al.[17] 
reported a false negative rate of 41% in a cohort of 1 014 hospitalised 
patients; the estimated median (standard deviation) interval between 
the initial negative test and subsequent positive RT-PCR result was 
5.1 (1.5) days. A selection of other studies reported false negative 
rates of between 3 and 29%.[18-20] Notably, some patients required up 
to five repeat tests before a positive result was ascertained.[19] This false 
negativity phenomenon may be the result of several factors, including 
a low viral load below the detection limit of the assay, low sample 
volume or cellular mass during acquisition, sampling location (upper 
v. lower respiratory tract), sample degradation during transport or 
storage, sample processing methodology and the timing of sampling 
in relation to the stage of the disease (RT-PCR positivity may 
progressively increase during the course of the disease).[14] 
Test accuracy will depend on the quality of the specimen 
collec ted.[20] It has since been shown that specimens from the lower 
respiratory tract have a higher viral load, and are hence more likely 
to test positive than specimens from the upper respiratory tract.[8,21] 
Nasopharyngeal specimens have better yield than oropharyngeal 
samples.[8,15] In hospitalised patients with severe disease, Wang et al.[8] 
found a sensitivity of 93% in bronchoalveolar lavage fluid (a high 
aerosol-generating procedure), 72% in sputum and 63% in nasal 
swabs; sensitivity ranged from 0 to 32% in pharyngeal swabs, faeces, 
blood and urine. Given these considerations, a negative test from an 
upper respiratory tract specimen should be repeated after 1 - 3 days 
(the optimal timing is unclear), or a lower respiratory tract specimen 
obtained to exclude a false negative result, if clinical suspicion is high.[22]
Viral shedding in asymptomatic, early prodromal and minimally 
symptomatic individuals, and after resolution of symptoms, helps 
to explain the rapid and extensive spread of COVID-19. In patients 
with more severe disease, including those with lower respiratory 
tract infection, but also in individuals with mild disease, high viral 
loads can often be detected for several days after the resolution of 
symptoms.[23] The significance of this remains unclear, although recent 
data from a limited number of patients suggest that RT-PCR positivity 
does not necessarily mean shedding of infectious virus after symptom 
resolution.[11] Zhifeng et al.[24] demonstrated that RT-PCR using 
nasopharyngeal samples can be negative even when there is computed 
tomography scan evidence of COVID-19 pneumonia.[24] Ali et al.[17] 
showed an improvement in disease extent in 42% of CT scans prior 
to RT-PCR tests becoming negative. It is unclear whether patients 
whose symptoms have resolved but who continue to have detectable 
viral RNA in respiratory samples can transmit infection. Furthermore, 
when symptoms have resolved, and especially given limited testing 
capacity, it remains unclear when patients may be discharged from the 
intensive care unit into the general ward setting, or from hospital into 
the community, especially if there are other individuals with high-risk 
profiles living in the same household. Therefore there are no clearly 
defined guidelines as to when it is safe for social mixing to occur after 
symptoms have resolved. Healthcare worker safety must be taken into 
account when collecting sputum, which should ideally be performed 
in an infection-controlled environment, or in the open air in ambulant 
patients. 
RT-PCR assays and their performance 
Currently, RT-PCR is the (imperfect) ‘gold standard’ for the diagnosis 
of COVID-19. The development of molecular detection assays has 
been facilitated by the sequencing of SARS-CoV-2.[25] The assay 
consists of two principal steps: (i) viral RNA extraction from patient 
specimens performed manually or using automated platforms; and 
(ii) reverse transcription and PCR amplification using specific primers 
and specific probes for real-time detection (see Fig. 1 for an overview). 
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The use of robotic systems allows for increased throughput for RNA 
extraction and PCR setup. Because of current resource constraints 
(trained personnel and reagents) and the necessity to rapidly deliver 
test outcomes, most diagnostic laboratories are skipping the post-
extraction RNA quality and quantification check, which is costly and 
labour intensive. 
Several SARS-CoV-2 targets are being used, and these include 
the envelope, nucleocapsid and RNA-dependent RNA polymerase 
(RdRp) genes, and two large open reading frames orf1a/orf1b, and 
Ribonuclease  P.[4] Generally, at least two target genes need to be 
identified for SARS-CoV-2 confirmation. However, interpretation 
algorithms differ with respect to the number of genes that need to be 
detected for the test to be considered positive. For some protocols, 
results are interpreted as indeterminate or negative if one of the genes 
is not detected, whereas for others, identification of one gene is used 
as screening test, while that of the subsequent gene(s) serves as a 
confirmatory test.[4] From a laboratory perspective, multiplexing of 
targets allows for better efficiency, shorter turnaround times and more 
optimal management of laboratory consumables.[26] Vogels et al.[27] 
evaluated nine primer-probe sets. They confirmed that each pair had 
a detection efficiency of >90%, but there were differences in the ability 
to differentiate true negatives from positives in patients with a low viral 
load. Some sets led to inconclusive results due to nonspecific background 
amplification (including the initial sets issued by the US Centers for 
Disease Control and Prevention but with subsequent rectification). 
With viral evolution, nucleotide substitutions may emerge that could 
affect primer/probe binding regions that could alter the sensitivity of 
PCR. Indeed, a potentially problematic mismatch in the RdRp-SARSr 
reverse primer has already been confirmed. The threshold cycle value 
of the target gene remains the quantitative endpoint to ascertain viral 
load and, depending on the kit used, this value generally lies in the 
30 - 40 range.[4,27] To control for nonspecific PCR inhibition, an internal 
positive amplification control (e.g. SARS-CoV-2 E-gene RNA, SARS-
CoV Frankfurt 1 RNA) is included in the assay, while a negative control 
interrogates for contamination during sample preparation. 
Digital PCR (dPCR) has been used to perform a quality assurance 
verification of RT-PCR.[28] dPCR involves partitioning a sample 
into many individual parallel PCR reactions, allowing even a single 
molecule to be amplified more than a million-fold. Using this 
technique, sensitivity was significantly improved from 28.2% by RT-
PCR to 87.4% by RT-dPCR.[28] Moreover, 15/16 close contacts in South 
Korea that were Guidelines for Laboratory Diagnosis of Coronavirus 
Disease 2019 (COVID-19)-inconclusive with conventional RT-PCR 
(likely because not all the targets of interest were detected) were dPCR-
positive. The overall sensitivity, specificity and diagnostic accuracy 
of RT-dPCR was 90%, 100% and 93%, respectively. Moreover, the 
higher sensitivity of RT-dPCR translated into detection of viral RNA 
for longer periods than with conventional RT-PCR in convalescing 
patients. While RT-dPCR is more sensitive and suitable for detecting 
low viral loads, its accessibility is limited by the complexity of the 
system and cost implications, and the inability to multiplex target 
genes of interest.[29] 
Fig. 1. Overview of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription polymerase chain reaction (RT-PCR)-based 
detection. Viral RNA extraction is performed from nasopharyngeal/oropharyngeal specimens using a manual or automated platform. RT-PCR is 
performed in a two-step assay. Extracted RNA is first reverse transcribed to make complementary DNA (cDNA). The cDNA is then amplified in 
the second step and fluorescence results from 5’-3’ exonuclease cleavage of a fluorescently-labelled target-specific probe enabling DNA amplification 
at each PCR cycle. (Ct = cycle threshold).
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Several automated rapid nucleic acid amplification tests have 
recently received Food and Drug Administration (FDA) approval for 
emergency use. Cepheid’s Xpert Xpress SARS-CoV-2, run on the Gene 
Xpert platform, detects multiple gene targets and can provide a result 
within 45 minutes (https://www.cepheid.com/coronavirus). Abbott’s 
rapid COVID-19 test, run on the Abbott ID NOW device, can provide 
results within 13 minutes (https://www.alere.com/en/home/product-
details/id-now-covid-19.html). The former may be convenient in 
countries such as South Africa (SA) that have an extensive Gene Xpert 
infrastructure, and the technology lends itself to onsite point-of-care 
testing using portable Xpert platforms such as Xpert Edge. 
While RT-PCR currently remains the imperfect gold standard for 
the rapid confirmation of SARS-CoV-2 infection, ongoing genetic 
evolution of the virus highlights the need to closely monitor and 
review the methodology based on emerging data. It is possible that 
a better stage-specific reference standard may emerge incorporating 
immunoassay results. 
Limited testing capacity remains a challenge to widespread 
surveillance and testing in SA. Expanding testing services to research-
based laboratories is fraught with challenges, including the need 
for accreditation of laboratories (by the South African National 
Accreditation System in SA) and personnel (by the Health Professions 
Council in SA). Capacity shortfalls are further compounded by an 
international and countrywide shortage of kits and reagents and a 
severe reduction in international freight shipping capacity. However, 
the implementation of rapid automated molecular testing (Xpert 
Xpress SARS-CoV-2) will be helpful if enough cartridges can be 
procured.
Immunoassays and their utility
Several antigen-based immunoassays have been developed that 
detect antibodies in serum or plasma.[30] One such assay was recently 
FDA approved, and the Foundation for Innovative New Diagnostics 
website lists over 200 companies that are either making or have made 
such assays.[31] Some are rapid lateral flow assay (LFA)-based while 
others are enzyme-linked immunosorbent assay (ELISA)-like tests. 
Both formats have antigen impregnated on a test line or on a plastic-
plate surface, and detect human IgG or IgM, and sometimes also IgA 
antibodies. In the meantime, rapid capture assays that detect viral 
antigens in nasopharyngeal aspirates have also been developed, and 
are being evaluated in tandem. 
Despite the proliferation of different testing devices and kits that are 
emerging, there are very few independent validation data on which 
specific assays work optimally. Therefore the sensitivity, specificity 
and predictive values of individual tests in different contexts remain 
unknown. A web-based resource has been developed that lists assays 
that have now been approved for use in specific countries.[32] Some 
tests purchased by specific countries have already been found not to 
meet expectations.[33] In Spain, one of worst-hit European nations, 
health authorities purchased thousands of rapid serological tests from 
a biotech company in China, but these were later found to have a 
sensitivity of ~30%.[34] SA companies have already produced iterations 
of LFA platforms, and they are currently being evaluated. 
One concern is test specificity, as there are four common human 
coronaviruses that cause up to a third of common cold episodes. 
Poorly designed antibody tests may cross-react with pre-existing anti-
coronavirus antibodies. High false-positivity rates may erroneously 
indicate disease in those without COVID-19, resulting in wasted 
public health contact-tracing efforts, unnecessary anxiety and even 
worse, unintended exposure of individuals to COVID-19 in testing 
centres and wards if they are hospitalised. Sub-optimal sensitivity with 
LFA formats without a signal amplification step is a potential concern 
as LFA, depending on the context, may have suboptimal sensitivity 
compared with ELISA-based assays. However, to what extent this 
applies to COVID-19 remains to be seen. 
Several recent articles describe longitudinal antibody responses 
in patients with COVID-19.[35-38] Broadly speaking, IgM responses 
tend to become detectable 3 - 7 days after the onset of symptoms.[37,39] 
Robust responses generally develop during the second week of 
illness.[35,36] Given these considerations, antibody-based tests are not 
recommended for first-line diagnosis within the first few days of 
symptoms. There is some evidence that combining antibody and RT-
PCR data during the early phase of disease may be useful and may 
have some incremental benefit, though further studies are required. 
However, the SA Health Products Regulatory Agency and other 
agencies have recently indicated, based on guidance from the SA 
National Institute of Communicable Diseases and the World Health 
Organization, that serological testing is not suitable for diagnosis of 
acute SARS CoV2 infection, and should be limited to epidemiological 
surveys (at least until more data become available).
Indeed, there is an undisputed role for immunoassays in surveillance 
studies, which may guide public health planning and help to define 
the trajectory of the epidemic. Their potential role for targeting 
vaccination in certain subgroups is being investigated. Some have 
suggested that immunoassays could identify previously infected and 
recovered healthcare workers and other essential workers who could 
potentially return to work, on the assumption that they are immune 
to reinfection. Whether this is the case, and for how long immunity 
lasts in the case of COVID-19, remains unclear. Therefore the validity 
of the concept of ‘immunity passports’ remains unclear.[40]
HIV-COVID-19 co-infected persons
There are currently no data on how diagnostic, management and 
prognostic considerations may be different in HIV-infected v. uninfected 
persons. In HIV-infected patients presenting with a respiratory 
tract infection, the general possibilities outlined above have to be 
considered, including considering Pneumocystis carinii pneumonia and 
TB in the differential diagnosis. Although well documented, it is not 
widely appreciated that between 10 and 20% of community-acquired 
pneumonia or acute lower respiratory tract infection in sub-Saharan 
Africa and parts of Asia is due to Mycobacterium tuberculosis[41-43], 
and this proportion is even higher in HIV-infected persons.[41,43] It is 
also possible that COVID-19 infection may unmask subclinical TB in 
both HIV-infected and uninfected persons. On the other hand, and 
particularly in HIV-infected persons, COVID-19 pneumonia, as in 
the case of influenza,[43] may be associated with a poorer prognosis in 
hospitalised patients with TB. Whether the SARS-CoV-2 viral load will 
be higher in HIV-infected persons, and therefore RT-PCR sensitivity 
better, remains unclear. In HIV-uninfected persons, co-infection with 
more than one pathogen has already been documented, e.g. co-infection 
with COVID-19 and influenza and/or bacterial organisms.[44] It is possible 
that co-infection with more than one pathogen may be more frequent 
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in HIV-infected persons or those with advanced immunosuppression. 
These unanswered questions will only be resolved once more data 
become available.
Summary and conclusions
The rapidly spreading COVID-19 pandemic has exposed capacity 
weaknesses in healthcare and laboratory testing systems. Although 
the mainstay of testing remains RT-PCR, there are several drawbacks, 
including a significant false negative rate in the early course of the 
disease, assay cost and lack of assay simplicity and the requirement for 
complex laboratory infrastructure. There is an emerging shortage of 
reagents, including RNA extraction kits, that is likely to worsen; already 
many centres are using dry nasopharyngeal swabs because of the 
shortage of viral transport medium. Antibody-based immunoassays 
have been developed, although they have a limited role in the early 
diagnosis of symptomatic patients. Their incremental benefit over RT-
PCR assays, and their role in other applications, including surveillance 
and targeting of individuals for vaccination and redeployment into the 
workforce, are under investigation.
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